The DOI matches its Crossref record.
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Open accessAbstract
To better understand the antibacterial activity of S-649266 against carbapenemase producers, its stability against clinically relevant carbapenemases was investigated. The catalytic efficiencies ( k cat / K m ) of IMP-1, VIM-2, and L1 for S-649266 were 0.0048, 0.0050, and 0.024 μM −1 s −1 , respectively, which were more than 260-fold lower than that for meropenem. Only slight hydrolysis of S-649266 against KPC-3 was observed. NDM-1 hydrolyzed meropenem 3-fold faster than S-649266 at 200 μM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Siderophores in Iron Metabolism: From Mechanism to Therapy Potential
Wilson, B. R., Bogdan, A. R., Miyazawa, M., Hashimoto, K., & Tsuji, Y. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.005 · Cited by 477
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Self-citationCefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Self-citationIto, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
“We have shown that this potent activity of cefiderocol is partly due to its high stability against various extended-spectrum -lactamases (ESBLs) and carbapenemases (26, 28).”
BackgroundSelf-citationNew Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Isler, B., Doi, Y., Bonomo, R. A., & Paterson, D. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01110-18 · Cited by 293
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Bahr, G., González, L. J., & Vila, A. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00138 · Cited by 266
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Wu, J. Y., Srinivas, P., & Pogue, J. M. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00286-6 · Cited by 195
Metadata
- Authors
- Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., & Tateda, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-07
- Volume
- 60
- Issue
- 7
- Pages
- 4384-4386
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2346730904
- Cited by
- 187
- References
- 0
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.